Opinion

Video

Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

Author(s):

Ronan J. Kelly, MD, MBA

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

Download PDF
Related Videos
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
Natural Killer Cells in Ovarian Cancer | Image Credit: © Dr_Microbe - stock.adobe.com
November 18th 2024

First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Matthew Vander Heiden, MD, PhD
November 1st 2024

Two Dana-Farber Cancer Institute Faculty Members Elected to the National Academy of Medicine

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Daniel DeAngelo MD, PhD, of Dana-Farber Cancer Institute
October 28th 2024

JAK Inhibitors Remain the Gold Standard in Myelofibrosis

David C. Fisher, MD
October 26th 2024

Bispecific Antibodies, Novel Combinations Highlight Continued Treatment Evolution in Follicular Lymphoma